Genfit Sa · EURONEXT:GNFT
Genfit Sa — J.P. Morgan Healthcare Conference 2026
14 slides from Genfit Sa's conference presentation, January 2026
Slide 1: Investor Presentation
Investor Presentation J . P. M o r g a n H e a l t h c a re C o n f e re n c e – S a n F ra n c i s c o Ja n u a r y 2026
Slide 2: Disclaimer
Disclaimer IMPORTANT NOTICE – YOU MUST READ THE FOLLOWING BEFORE CONTINUING. THIS PRESENTATION HAS BEEN PREPARED BY GENFIT AND IS FOR INFORMATION PURPOSES ONLY. CERTAIN OF THE INFORMATION CONTAINED HEREIN CONCERNING ECONOMIC TRENDS AND PERFORMANCE IS BASED UPON OR DERIVED FROM INFORMATION PROVIDED B
Slide 3: Exec Summary
Exec Summary Iqirvo®: Strong commercial sales1 trajectory in PBC 1 • Key contributing factor to GENFIT ‘s robust financial position • Next update by IPSEN: February 12, 2026 G1090N in ACLF: Safety profile and anti-inflammatory activity 2 • A promising investigational candidate for patients with ACLF
Slide 4: Corporate Highlights
Corporate Highlights French biopharmaceutical company ACLF Continuum3 Listed on EURONEXT “GNFT” • Lead asset: G1090N • Other assets: SRT-015 | CLM-022 | VS-02-HE 25+ years in liver diseases, taking | EViv (Research collaboration) early assets to commercial stage1 CCA Our Focused on rare, severe live
Slide 5: Solid Commercial Performance from Ipsen in PBC
PBC Solid Commercial Performance from Ipsen in PBC 1. 2. Rapid regulatory approvals1 Successful commercial launch Iqirvo® sales (global, quarterly) since commercial launch2 $144.4M 2024 2025 $56.0M FDA 3 major EU $88.4M countries $39.7M Feb12 2026 Reimbursement $48.7M IPSEN 2025 EMA results $24.6M $
Slide 6: ACLF: A High Unmet Need
ACLF ACLF: A High Unmet Need CHRONIC PHASE ACUTE PHASE Acute Chronic Liver Disease Cirrhosis ACLF 23-74% mortality at 28 days Decompensation = UNDERLYING CONDITION = PRECIPITANT ≥ 1 ORGAN DYSFUNCTIONS/FAILURES ► NO APPROVED DRUGS Bacterial Alcohol Alcohol Viruses Kidney Cerebral Infection Consumptio
Slide 7: A Strong Scientific Rationale for investigational drug G1090N, Our Lead Asset in ACLF
A Strong Scientific Rationale for investigational drug G1090N, Our Lead Asset in ACLF Findings to date: G1090N ✓ Decreases systemic inflammation in animal models, including in ACLF models ✓ Protects liver, kidney & brain in rat models of ACLF by decreasing tissue damages Anti-inflammatory Oral ✓ Pro
Slide 8: G1090N's Potential Recently Confirmed in the Clinic
G1090N’s Potential Recently Confirmed in the Clinic G1090N Anti-inflammatory Oral The safety profile observed in Phase 1 and the consistent biological activity evidenced in ex vivo assays represent a meaningful step in development. These findings position G1090N as a promising candidate for patients
Slide 9: CCA with KRAS mutation: A High Unmet Need
Onco CCA with KRAS mutation: A High Unmet Need Rare and aggressive liver malignancy ~30% of patients with CCA harbour KRAS mutations4 that develops in the bile ducts • one of the most common genes that might be mutated or amplified resulting in the overactivation of some of these pathways5 • As the
Slide 10: Rationale for Combining Anticancer Therapies and investigational drug GNS561, an Autophagy Inhibitor
Rationale for Combining Anticancer Therapies and investigational drug GNS561, an Autophagy Inhibitor GNS561 PPT1 inhibitor in #1 Anticancer Therapies combination with a MEK inhibitor Oral #2 GNS561 Chemotherapeutic agents (Autophagy inhibitor) MAP Kinase pathway targeted therapies By entering the ly
Slide 11: Phase 1b: Highly Encouraging Early Data
Phase 1b: Highly Encouraging Early Data GNS561 PPT1 inhibitor in combination with a MEK inhibitor Oral Advanced KRAS-mutated cholangiocarcinoma remains a formidable clinical challenge, and the emerging activity seen in this initial study is encouraging. Because MEK inhibition alone has historically
Slide 12: Moving Forward
Moving Forward • Phase 1b dose escalation will continue as planned to confirm activity signal • 1Q2026 - New data from next patient cohorts expected • 1H2026 - Completion expected results will be used to establish recommended Phase 2 combination doses • 2H2026 – targeted Phase 2 initiation Beyond CC
Slide 13: Other R&D Programs
Other Other R&D Programs ACLF Continuum UCD/OA Research Collaboration with EVerZom1 SRT-015 CLM-022 VS-02-HE EViv VS-01-HAC Injectable Oral Injectable Peritoneal ASK1 NLRP3 inflammasome Urease Exosome Liposomal-based inhibitor inhibitor inhibitor Technology technology To inhibit apoptosis, To inhibi
Slide 14: Targeting Untapped Markets with High Potential
Market Targeting Untapped Markets with High Potential ACLF Oncology Prevalence of ACLF 294,000 in 2021, US, EU4, UK Prevalence of CCA ~$3.1Bn 20,000 to 30,000 for US, EU4, UK Market estimates for CCA ~300,000 by 2036 for US, EU4, UK Growing at Epidemic Rates +26% between 2006 and 2014 1 ~€160-200M P